// App-Quantinova.ai

POS0894 (2021) : ANTI-IL-6 THERAPY EFFECT FOR REFRACTORY JOINT AND SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS: A REAL-WORLD, SINGLE CENTER EXPERIENCE

Researchers

Presenter

  • S. Panopoulos

Principal Investigators

  • M. Tektonidou

  • V. K. Bournia

  • A. Arida

  • P. Sfikakis

Medical Centers

  • National and Kapodistrian University of Athens, First Propedeutic and Internal Medicine, Joint Rheumatology Program, Medical School, Athens, Greece

Locations

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • Scleroderma

  • Autoimmune sclerosing cholangitis

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • Glutathione S-transferase Zeta 1

Drug/Treatment

  • Hydroxychloroquine

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • Methotrexate

  • Tocilizumab

  • leflunomide

  • Rituximab

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved